11,360 Shares in Hologic, Inc. $HOLX Bought by Alamea Verwaltungs GmbH

Key Points

• Alamea Verwaltungs GmbH has acquired 11,360 shares of Hologic, Inc. valued at approximately $702,000, making it the firm's 19th largest position.
• Hologic recently reported quarterly earnings of $1.08 EPS, surpassing analysts' estimates and showing a 1.2% year-over-year revenue increase to $1.02 billion.
• Institutional investors hold around 94.73% of Hologic’s stock, indicating strong institutional support for the company.

Alamea Verwaltungs GmbH acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 11,360 shares of the medical equipment provider's stock, valued at approximately $702,000. Hologic comprises about 0.6% of Alamea Verwaltungs GmbH's investment portfolio, making the stock its 19th largest position.

Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. Victory Capital Management Inc. boosted its holdings in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after purchasing an additional 1,692,177 shares during the last quarter. Nuance Investments LLC raised its position in shares of Hologic by 623.7% during the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock valued at $66,794,000 after buying an additional 931,920 shares in the last quarter. Redwood Wealth Management Group LLC purchased a new stake in shares of Hologic during the 1st quarter valued at about $3,534,000. Invesco Ltd. raised its position in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after buying an additional 764,573 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Hologic during the 1st quarter valued at about $30,317,000. Institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

Hologic stock opened at $67.12 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The firm has a market capitalization of $14.93 billion, a P/E ratio of 27.85, a price-to-earnings-growth ratio of 2.44 and a beta of 0.49. The company's 50-day moving average is $66.15 and its 200 day moving average is $62.50.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $1.06 EPS. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on HOLX shares. Stephens decreased their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and upped their target price for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. UBS Group upped their target price on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Morgan Stanley upped their target price on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.